The search for effective treatment of coronavirus has two fundamental approaches. One is to treat those who have already been infected by the virus. The second is to prevent active infection using vaccines.
Research must involve many different innovative approaches. The purpose of this post is to communicate one possible method of treatment for individuals who are infected.
HEPES is a biological response modifier (BRM). It is one of a group known as zwitterions. Dr. Norman Good discovered the molecule in 1966. Dr. Good demonstrated that HEPES (and other zwitterions) increased mitochondrial activity. It raised the rate of oxidative phosphorylation (a basic reaction in metabolism). Dr. Good focused on the ability of HEPES capacity to act as a buffer. For years HEPES was considered just a buffer. In 1997 I described numerous effects of HEPES as a biological response modifier.
HEPES is a true biological response modifier (BRM). The effects of HEPES as broad immune stimulant and its effects on cytokines has been demonstrated. Effects are dose dependent. HEPES anti-viral effect has been noted. HEPES has also been shown to inhibit the conversion of prion protein. HEPES has been shown to improve O2 saturation in COPD. HEPES primary action is in the mitochondria and increases the rate of oxidative phosphorylation.
In our original work in 1996 we described the apparent radioprotective effects of HEPES. Noting that HEPES as a biological response modifier (BRM) was apparently radioprotective in patients with radiation implant exposure.
There was further validation by Sasson https://lnkd.in/dbKdafs in 2010.
Mitochondrial activity: HEPES and other zwitterions are true biological response modifiers. Years ago they were discovered by Dr. Norman Good at Roswell Park. It is interesting that he concentrated on their effects as a “buffer”. Dr. Good noted that HEPES and the other “Good buffers” increased the rate of oxidative phosphorylation in mitochondria. HEPES showed the greatest increase. I described the biological response modifying effects of HEPES “buffers” in 1998. Among the many effects of HEPES, it was shown that the compound induced “extramedullary hematopoiesis”. As much research is directed towards drugs that effect mitochondria – Perhaps it is time to look back at something that really works. For instance, if a compound can increase mitochondrial activity – what effect does this have on disease processes?
A new patented system for an Optical Firewall provides a paradigm shift in the approach to preventing unauthorized access to server/mainframe data. The system is hardware based and entitled “System and Method for Optical Security Firewalls In Computer Communication Systems”. (US Patent 9,584,475).
It is a method and system for a bidirectional firewall in computer communications, which utilizes the transfer of information from an optical display to a separate server thereby eliminating unauthorized entry into the server and prohibiting access to the stored information.
We report a pilot toxicity study in healthy beagle dogs which revealed no significant adverse events for TVZ-7 given at i.v. doses up to 520 mg/kg/day. All treated dogs displayed calm behavior and maintained normal clinical laboratory values throughout the study. Increased bone marrow hypercellularity and extramedullary hematopoiesis was also noted in these dogs.
One of the zwitterion buffers that has shown significant therapeutic value in the treatment of pain due to cancer, immunologically mediated diseases, and the pain associated with these conditions is in the class of N-substituted amino-sulfonic acids known as “Good Buffers.” Zwitterion molecules have neither a negative nor a positive charge; thus, they are neutral. 4-(2 Hydroxyethyl)-1-piperazine ethane sulfonic acid has been used for several decades in artificial biological systems (tissue culture) as a buffer.
The article is entitled:”Monoclonal antibodies for Emerging Infectious Disease – Borrowing from History” authored by H.D. Marston, M.D., MPH, Catherine I. Paules, M.D., and Anthony S. Fauci,M.D NEJM March 7,2018.
http://www.nejm.org/doi/full/10.1056/NEJMp1802256
The article discusses a brief history of using monoclonal antibodies as treatment for non-communicable diseases. It also states that a few monoclonal therapies have been approved for treatment of infectious diseases.The use of monoclonal antibodies to treat viral diseases is an important scientific approach to research.
The Letter to the Editor on the article :”Monoclonal antibodies for Emerging Infectious Disease – Borrowing from History” H.D. Marston, M.D., MPH, Catherine I. Paules, M.D., and Anthony S. Fauci,M.D., NEJM March 7,2018 remains unanswered as does my letter to the NIH..
However this week (April 19, 2018 edition) the NEJM republished the March 7, 2018 article with the addition of an audio interview with Dr. Anthony Fauci. How unusual to republish the article with further audio comment?